Tislelizumab

Tislelizumab, a monoclonal antibody with high binding affinity to the PD-1 receptor, minimizes Fcγ receptor binding on macrophages, thereby abrogating antibody-dependent phagocytosis, a mechanism of T cell clearance and potential resistance to anti-PD-1 research. Tislelizumab can be used for the research of advanced squamous non-small-cell lung cancer.
Read more
€0.00 (tax incl.)
Reference:
HY-P99052
Product Details
HY-P99052

Data sheet

Size
Multiple sizes
Reactivity
PD-1/PD-L1
Application
COVID-19-immunoregulation
CAS
1858168-59-8

Menu

Settings